secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001628280-26-030677
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta Q2 revenue $145M, GAAP EPS -$3.41; cuts FY2026 guidance, extends long-range plan to 2029
--------------------------------------------------------------------------------

- Organic revenue declined 3% YoY; $149M non-cash goodwill impairment on Multiomics unit.
- FY2026 organic growth guidance cut to -2% to +1% (prev. 3-5%); Adj. EBITDA margin now -125bps to flat.
- Long-range plan extended from 2028 to 2029; B Medical Systems sale delayed due to buyer financing.
- Non-GAAP diluted EPS -$0.04 vs. +$0.01 prior year; cash and securities $565M; no share repurchases yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000162828026030677/0001628280-26-030677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000162828026030677/azta-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-030677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer